 Marinus Pharmaceuticals, Inc. MRNS, a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided a pipeline update in advance of it clinical and commercial overview webinar to be held today, Tuesday, June 30, 2020 from 8am 10:30am Eastern Time. With a final protocol in place, we are on-track to begin our Phase 3 pivotal trial in status epilepticus next quarter, said Scott Braunstein, M.D., Chief Executive Officer of Marinus. Our Phase 3 trial is designed to demonstrate both rapid onset of antiepileptic activity along with sustained status cessation, allowing physicians to focus their attention on the patients underlying disease state and avoid the often devastating consequences of uncontrolled SE and anesthesia induced coma. 